Gleamer

Gleamer is a France-based developer of a radiology technology designed to detect and highlight bone abnormalities. The company's technology utilizes an artificial intelligence (AI)-based assistant to automatically detect lesions on trauma X-rays and provides preliminary data for diagnosis on standard radiography, enabling radiologists to avoid missing tiny lesions. It was founded in December 2017 and has an office in the United States in addition to its headquarters in Paris, France.

Gleamer developed an AI-powered platform that is intended to be used by radiologists for clinical applications, such as the detection of anomalies in bone trauma scans.

Gleamer developed the first prototype of its platform in 2018. The name of the platform is BoneView, and it was developed specifically for medical professionals to detect fractures on X-rays. The platform was cleared for use with its CE medical device certification (class IIA), which allowed it to be used across Europe and other countries that recognize that label. In 2022, the Food and Drug Administration (FDA) approved the platform for usage in the United States.

Gleamer has developed specialized features for its BoneView platform. BoneView Trauma iis designed to detect tiny lesions in X-ray images that are sometimes missed by the human eye. BoneView Age aids radiologists with an age assessment of a bone. Finally, BoneView Measurements automates standard measurements and then turns them into a report that uses structured visuals to show the acquired data.

ChestView is the second AI solution that was developed by Gleamer, and it was launched in 2022. This platform provides radiologists and other related medical professionals with an automated second reading of chest X-rays. The platform allows medical professionals to detect subtle, small abnormalities in the chest region, which can be used for applications such as early cancer detection.